Ieuan Jones
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Journal: Clinical pharmacology in drug development
Published: October 18, 2023
Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: October 17, 2023
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
Journal: The European respiratory journal
Published: June 10, 2022
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
Journal: Respiratory research
Published: August 12, 2021
Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma.
Journal: Clinical drug investigation
Published: March 22, 2021
Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial.
Journal: ERJ open research
Published: June 24, 2020
Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: May 21, 2020
Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial.
Journal: International journal of chronic obstructive pulmonary disease
Published: April 08, 2020
Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
Journal: Respiratory research
Published: December 23, 2019
Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Journal: The Journal of allergy and clinical immunology
Published: April 01, 2015
Bayesian Design of Proof-of-Concept Trials.
Journal: Therapeutic innovation & regulatory science
Published: January 01, 2015
Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.
Journal: The Journal of allergy and clinical immunology
Published: May 29, 2014
Last Updated: 09/26/2026